Clinical Trials
3 trialsNCT06006013 2026-02-18
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
Phase 2 Recruiting
NCT02721732 2026-01-29
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04373265 2024-02-23
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
Corcept Therapeutics
Phase 1 Completed